Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Effects of shared decision making on distress and healthcare utilization among patients with lung cancer: a systematic review.

Geerse OP, Stegmann ME, Kerstjens HAM, Hiltermann TJN, Bakitas M, Zimmermann C, Deal AM, Brandenbarg D, Berger MY, Berendsen AJ.

J Pain Symptom Manage. 2018 Aug 23. pii: S0885-3924(18)30441-X. doi: 10.1016/j.jpainsymman.2018.08.011. [Epub ahead of print] Review.

PMID:
30145213
2.

Correspondence between primary and secondary care about patients with cancer: A qualitative mixed-methods analysis.

Stegmann ME, Meijer JM, Nuver J, Havenga K, Hiltermann TJN, Maduro JH, Schuling J, Berendsen AJ.

Eur J Cancer Care (Engl). 2018 Aug 23:e12903. doi: 10.1111/ecc.12903. [Epub ahead of print]

PMID:
30138956
3.

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers.

Wei J, van der Wekken AJ, Saber A, Terpstra MM, Schuuring E, Timens W, Hiltermann TJN, Groen HJM, van den Berg A, Kok K.

Cancers (Basel). 2018 Jan 4;10(1). pii: E10. doi: 10.3390/cancers10010010.

4.

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.

van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den Berg A, Groen HJM.

PLoS One. 2017 Aug 30;12(8):e0182885. doi: 10.1371/journal.pone.0182885. eCollection 2017.

5.

Transient thyrotoxicosis during nivolumab treatment.

van Kooten MJ, van den Berg G, Glaudemans AWJM, Hiltermann TJN, Groen HJM, Rutgers A, Links TP.

Neth J Med. 2017 Jun;75(5):204-207.

6.

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators.

N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.

7.

A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14).

Boshuizen RC, Vd Noort V, Burgers JA, Herder GJM, Hashemi SMS, Hiltermann TJN, Kunst PW, Stigt JA, van den Heuvel MM.

Lung Cancer. 2017 Jun;108:9-14. doi: 10.1016/j.lungcan.2017.01.019. Epub 2017 Feb 16.

PMID:
28625655
8.

[New biopsy at lung cancer progression: rational treatment of resistant lung cancer].

Hijmering-Kappelle LBM, van der Wekken AJ, Hiltermann TJN, Groen HJM.

Ned Tijdschr Geneeskd. 2017;161:D1229. Review. Dutch.

PMID:
28558851
9.

Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small-cell lung cancer patient.

Ferronika P, van den Bos H, Taudt A, Spierings DCJ, Saber A, Hiltermann TJN, Kok K, Porubsky D, van der Wekken AJ, Timens W, Foijer F, Colomé-Tatché M, Groen HJM, Lansdorp PM, van den Berg A.

Ann Oncol. 2017 Jul 1;28(7):1668-1670. doi: 10.1093/annonc/mdx182. No abstract available.

PMID:
28419234
10.

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer.

van der Wekken AJ, Pelgrim R, 't Hart N, Werner N, Mastik MF, Hendriks L, van der Heijden EHFM, Looijen-Salamon M, de Langen AJ, Staal-van den Brekel J, Riemersma S, van den Borne BE, Speel EJM, Dingemans AC, Hiltermann TJN, van den Berg A, Timens W, Schuuring E, Groen HJM.

Clin Cancer Res. 2017 Aug 1;23(15):4251-4258. doi: 10.1158/1078-0432.CCR-16-1631. Epub 2017 Feb 9.

11.

Study protocol for the OPTion randomised controlled trial on the effect of prioritising treatment goals among older patients with cancer in a palliative setting.

Stegmann ME, Schuling J, Hiltermann TJ, Reyners AK, Burger H, Berger MY, Berendsen AJ.

Maturitas. 2017 Feb;96:84-88. doi: 10.1016/j.maturitas.2016.11.014. Epub 2016 Nov 27.

PMID:
28041600
12.

Structural distress screening and supportive care for patients with lung cancer on systemic therapy: A randomised controlled trial.

Geerse OP, Hoekstra-Weebers JE, Stokroos MH, Burgerhof JG, Groen HJ, Kerstjens HA, Hiltermann TJ.

Eur J Cancer. 2017 Feb;72:37-45. doi: 10.1016/j.ejca.2016.11.006. Epub 2016 Dec 23.

PMID:
28024265
13.

Mutation patterns in small cell and non-small cell lung cancer patients suggest a different level of heterogeneity between primary and metastatic tumors.

Saber A, Hiltermann TJN, Kok K, Terpstra MM, de Lange K, Timens W, Groen HJM, van den Berg A.

Carcinogenesis. 2017 Feb 1;38(2):144-151. doi: 10.1093/carcin/bgw128.

PMID:
27993895
14.

Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer.

Pore M, Meijer C, de Bock GH, Boersma-van Ek W, Terstappen LW, Groen HJ, Timens W, Kruyt FA, Hiltermann TJ.

Clin Lung Cancer. 2016 Nov;17(6):535-542. doi: 10.1016/j.cllc.2016.05.015. Epub 2016 Jun 8.

PMID:
27363902
15.

Health-related problems in adult cancer survivors: development and validation of the Cancer Survivor Core Set.

Geerse OP, Wynia K, Kruijer M, Schotsman MJ, Hiltermann TJ, Berendsen AJ.

Support Care Cancer. 2017 Feb;25(2):567-574. doi: 10.1007/s00520-016-3439-0. Epub 2016 Oct 14.

16.
17.

An exploratory study of volumetric analysis for assessing tumor response with (18)F-FAZA PET/CT in patients with advanced non-small-cell lung cancer (NSCLC).

Kerner GS, Bollineni VR, Hiltermann TJ, Sijtsema NM, Fischer A, Bongaerts AH, Pruim J, Groen HJ.

EJNMMI Res. 2016 Dec;6(1):33. doi: 10.1186/s13550-016-0187-6. Epub 2016 Apr 18.

18.

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.

Saber A, van der Wekken AJ, Kok K, Terpstra MM, Bosman LJ, Mastik MF, Timens W, Schuuring E, Hiltermann TJ, Groen HJ, van den Berg A.

PLoS One. 2016 Apr 5;11(4):e0153065. doi: 10.1371/journal.pone.0153065. eCollection 2016.

19.

Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer.

Saber A, van der Wekken AJ, Kerner GS, van den Berge M, Timens W, Schuuring E, ter Elst A, van den Berg A, Hiltermann TJ, Groen HJ.

PLoS One. 2016 Mar 23;11(3):e0152317. doi: 10.1371/journal.pone.0152317. eCollection 2016.

20.

Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature.

van der Wekken AJ, Saber A, Hiltermann TJ, Kok K, van den Berg A, Groen HJ.

Crit Rev Oncol Hematol. 2016 Apr;100:107-16. doi: 10.1016/j.critrevonc.2016.01.024. Epub 2016 Jan 25. Review.

21.

The detection of EpCAM(+) and EpCAM(-) circulating tumor cells.

de Wit S, van Dalum G, Lenferink AT, Tibbe AG, Hiltermann TJ, Groen HJ, van Rijn CJ, Terstappen LW.

Sci Rep. 2015 Jul 17;5:12270. doi: 10.1038/srep12270.

22.

An instrument dedicated for modelling of pulmonary radiotherapy.

Niezink AG, Dollekamp NJ, Elzinga HJ, Borger D, Boer EJ, Ubbels JF, Woltman-van Iersel M, van der Leest AH, Beijert M, Groen HJ, Kraan J, Hiltermann TJ, van der Wekken AJ, van Putten JW, Rutgers SR, Pieterman RM, de Hosson SM, Roenhorst AW, Langendijk JA, Widder J.

Radiother Oncol. 2015 Apr;115(1):3-8. doi: 10.1016/j.radonc.2015.03.020. Epub 2015 Apr 9.

PMID:
25866028
23.

The value of proteomics in lung cancer.

van der Wekken AJ, Hiltermann TJ, Groen HJ.

Ann Transl Med. 2015 Mar;3(3):29. doi: 10.3978/j.issn.2305-5839.2015.01.10.

24.

Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer.

Kerner GS, van Dullemen LF, Wiegman EM, Widder J, Blokzijl E, Driever EM, van Putten JW, Liesker JJ, Renkema TE, Pieterman RM, Mertens MJ, Hiltermann TJ, Groen HJ.

Radiat Oncol. 2014 Aug 29;9:190. doi: 10.1186/1748-717X-9-190.

25.

Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.

Kerner GS, Schuuring E, Sietsma J, Hiltermann TJ, Pieterman RM, de Leede GP, van Putten JW, Liesker J, Renkema TE, van Hengel P, Platteel I, Timens W, Groen HJ; CTMM Air Force Consortium.

PLoS One. 2013 Jul 29;8(7):e70346. doi: 10.1371/journal.pone.0070346. Print 2013.

26.

Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation.

van Geffen WH, Hiltermann TJ, Groen HJ.

J Thorac Oncol. 2013 Jan;8(1):e1-2. doi: 10.1097/JTO.0b013e3182762812. No abstract available.

27.

Moving forward with circulating tumor cells and lung cancer.

Hiltermann TJ, van der Wekken AJ, Groen HJ.

J Thorac Dis. 2012 Oct;4(5):440-1. doi: 10.3978/j.issn.2072-1439.2012.08.08. No abstract available.

28.

Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor.

Hiltermann TJ, Pore MM, van den Berg A, Timens W, Boezen HM, Liesker JJ, Schouwink JH, Wijnands WJ, Kerner GS, Kruyt FA, Tissing H, Tibbe AG, Terstappen LW, Groen HJ.

Ann Oncol. 2012 Nov;23(11):2937-42. doi: 10.1093/annonc/mds138. Epub 2012 Jun 11.

PMID:
22689177
29.

[New 'targeted therapy' for lung cancer].

Groen HJ, Hiltermann TJ, Schuuring E, Timens W.

Ned Tijdschr Geneeskd. 2011;155(45):A4081. Dutch.

PMID:
22085575
30.

Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.

Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM.

J Clin Oncol. 2011 Nov 10;29(32):4320-6. doi: 10.1200/JCO.2011.35.5214. Epub 2011 Oct 11.

PMID:
21990410
31.

[Desensitisation to circumvent hypersensitivity reactions; treatment with docetaxel still possible].

Luiting J, de Monchy JG, Hiltermann TJ, Oude Elberink JN.

Ned Tijdschr Geneeskd. 2011;155:A2980. Dutch.

PMID:
21527052
32.

A malignant retroperitoneal mass--a rare presentation of recurrent thymoma.

van Geffen WH, Sietsma J, Roelofs PM, Hiltermann TJ.

BMJ Case Rep. 2011 Dec 1;2011. pii: bcr0920114737. doi: 10.1136/bcr.09.2011.4737.

33.

Targeting apoptosis pathways in lung cancer.

Pore MM, Hiltermann TJ, Kruyt FA.

Cancer Lett. 2013 May 28;332(2):359-68. doi: 10.1016/j.canlet.2010.09.012. Epub 2010 Oct 25. Review.

PMID:
20974517
34.

Bilateral cavitary pulmonary consolidations in a patient undergoing allogeneic bone marrow transplantation for acute leukemia.

Hiltermann TJ, Bredius RG, Gesink-vd Veer BJ, Corrin B, Rabe KF, Brahim JJ.

Chest. 2003 Mar;123(3):929-34. No abstract available.

PMID:
12628896
35.

Experimental rhinovirus 16 infection increases intercellular adhesion molecule-1 expression in bronchial epithelium of asthmatics regardless of inhaled steroid treatment.

Grünberg K, Sharon RF, Hiltermann TJ, Brahim JJ, Dick EC, Sterk PJ, Van Krieken JH.

Clin Exp Allergy. 2000 Jul;30(7):1015-23.

PMID:
10848925
36.

Ozone-induced airway hyperresponsiveness in patients with asthma: role of neutrophil-derived serine proteinases.

Hiltermann TJ, Peters EA, Alberts B, Kwikkers K, Borggreven PA, Hiemstra PS, Dijkman JH, van Bree LA, Stolk J.

Free Radic Biol Med. 1998 Apr;24(6):952-8.

PMID:
9607605
37.

Asthma severity and susceptibility to air pollution.

Hiltermann TJ, Stolk J, van der Zee SC, Brunekreef B, de Bruijne CR, Fischer PH, Ameling CB, Sterk PJ, Hiemstra PS, van Bree L.

Eur Respir J. 1998 Mar;11(3):686-93.

38.

Effects of photochemical air pollution and allergen exposure on upper respiratory tract inflammation in asthmatics.

Hiltermann TJ, de Bruijne CR, Stolk J, Zwinderman AH, Spieksma FT, Roemer W, Steerenberg PA, Fischer PH, van Bree L, Hiemstra PS.

Am J Respir Crit Care Med. 1997 Dec;156(6):1765-72.

PMID:
9412553
39.

Effect of ozone exposure on maximal airway narrowing in non-asthmatic and asthmatic subjects.

Hiltermann TJ, Stolk J, Hiemstra PS, Fokkens PH, Rombout PJ, Sont JK, Sterk PJ, Dijkman JH.

Clin Sci (Lond). 1995 Dec;89(6):619-24.

PMID:
8549080
40.

Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol.

Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ.

Am J Respir Cell Mol Biol. 1994 Jul;11(1):95-102.

PMID:
8018341

Supplemental Content

Loading ...
Support Center